Stanowisko polskich ekspertów dotyczące zastosowania leku brentuksymab vedotin w leczeniu chorych na pierwotne chłoniaki skóry CD30+

Q4 Medicine

Hematologia Pub Date : 2018-08-17 DOI:10.5603/HEM.2018.0015

Małgorzata Sokołowska-Wojdyło, J. Walewski, W. Jędrzejczak, T. Robak, Monika Prochorec-Sobieszek, Joanna Zaucha, Alina Jankowska-Konsur, M. Słowińska, E. Chmielowska, L. Rudnicka, Sebastian Giebel

{"title":"Stanowisko polskich ekspertów dotyczące zastosowania leku brentuksymab vedotin w leczeniu chorych na pierwotne chłoniaki skóry CD30+","authors":"Małgorzata Sokołowska-Wojdyło, J. Walewski, W. Jędrzejczak, T. Robak, Monika Prochorec-Sobieszek, Joanna Zaucha, Alina Jankowska-Konsur, M. Słowińska, E. Chmielowska, L. Rudnicka, Sebastian Giebel","doi":"10.5603/HEM.2018.0015","DOIUrl":null,"url":null,"abstract":"The group of primary cutaneous T-cell lymphomas (CTCLs) expressing CD30 + is consisted of primary cutaneous anaplastic T-cell lymphoma (pcACTL), lymphomatoid papulosis (LyP), some cases of mycosis fungoides (MF) and Sezary syndrome (SS). It is well known that patient cannot be cured completely by available therapeutic methods. In addition, the effectiveness of available therapies is especially limited in advanced stages of the disease. Based on the results of the most recent trials, the experts recommend that brentuximab vedotin (BV) should be reimbursed in Poland for the treatment of adult patients with CTCL expressing CD30 who have had at least one prior systemic treatment. In case of MF BV should be preferred to bexarotene or MTX therapy due to the higher efficacy in stage IIB or higher. BV treatment should be also considered as an alternative to bexarotene (after ineffectiveness of local treatment, phototherapy and IFN/MTX therapy) in early stages of MF (IB-IIA).","PeriodicalId":38988,"journal":{"name":"Hematologia","volume":"4 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2018-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hematologia","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5603/HEM.2018.0015","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

The group of primary cutaneous T-cell lymphomas (CTCLs) expressing CD30 + is consisted of primary cutaneous anaplastic T-cell lymphoma (pcACTL), lymphomatoid papulosis (LyP), some cases of mycosis fungoides (MF) and Sezary syndrome (SS). It is well known that patient cannot be cured completely by available therapeutic methods. In addition, the effectiveness of available therapies is especially limited in advanced stages of the disease. Based on the results of the most recent trials, the experts recommend that brentuximab vedotin (BV) should be reimbursed in Poland for the treatment of adult patients with CTCL expressing CD30 who have had at least one prior systemic treatment. In case of MF BV should be preferred to bexarotene or MTX therapy due to the higher efficacy in stage IIB or higher. BV treatment should be also considered as an alternative to bexarotene (after ineffectiveness of local treatment, phototherapy and IFN/MTX therapy) in early stages of MF (IB-IIA).

查看原文本刊更多论文

表达CD30 +的原发性皮肤t细胞淋巴瘤(CTCLs)组包括原发性皮肤间变性t细胞淋巴瘤(pcACTL)、类淋巴瘤丘疹病(LyP)、部分蕈样真菌病(MF)和Sezary综合征(SS)。众所周知，现有的治疗方法不能完全治愈病人。此外，在疾病的晚期，现有疗法的有效性尤其有限。根据最近的试验结果，专家们建议，在波兰，对于表达CD30且至少接受过一次全身治疗的成年CTCL患者，brentuximab vedotin (BV)治疗应该报销。在MF BV的情况下，应优先考虑贝沙罗汀或甲氨蝶呤治疗，因为在IIB期或更高的疗效更高。在MF (IB-IIA)的早期阶段，BV治疗也应考虑作为贝沙罗汀的替代方案(在局部治疗、光疗和IFN/MTX治疗无效后)。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Hematologia Medicine-Oncology

自引率

0.00%

发文量

审稿时长

4 weeks

期刊介绍： Hematology is the quarterly under auspices of the Institute of Hematology and Transfusion Medicine. The journal is addressed to hematologists, oncologists and also internists. It contains the overview/review articles, case reports, essays, including reports from the scientific and educational conferences as well as test questions on hematology. Journal of the Institute of Hematology and Transfusiology.